AI Science Tracker
EN

Biotechnology Research Unit

1 discovery from 2023

Discoveries

Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy

Source check: Source checked. Not independent scientific confirmation.

Finding: Original full text, Methods/Results: autoencoder and SHAP feature selection on expression profiles yielded CLL therapy-need/time-to-first-treatment model; prospective observational cohort but model evaluation retrospective (217 analyzed); test AUC 0.91. Prognostic association, not prospective clinical utility. Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations.

Technology: Autoencoder and SHAP gene-selection workflow

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Uses expression-profile features selected with an autoencoder and SHAP to model CLL therapy need and time to first treatment.
Test and result
Original full text, Methods/Results: autoencoder and SHAP feature selection on expression profiles yielded CLL therapy-need/time-to-first-treatment model; prospective observational cohort but model evaluation retrospective (217 analyzed); test AUC 0.91. Prognostic association, not prospective clinical utility.
Limitation / still unknown
Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations. The source does not establish benefits beyond the reported evaluation.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1198992/full · https://europepmc.org/article/MED/37719021

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.